Phaseline

Companies › Kexing Biopharm

Kexing Biopharm: clinical trials, targets and expected readouts

4 active drug programs in 12 registered trials: 8 Phase 3, 2 Phase 1, 2 Phase 2; Oncology, Metabolic and endocrine, Infectious disease, Hematology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Human interferon α1b Inhalation Solution
Interferon alpha-1b, antiviral cytokine
IFNA1Phase 3Respiratory Syncytial Virus InfectionsJun 2027
GB06
Recombinant human growth hormone (biosimilar)
GH1Phase 3Growth Hormone Deficiency (GHD)Jul 2028
Pegfilgrastim
Granulocyte colony stimulating factor receptor agonist
CSF3RPhase 3Neutropenia, Chemotherapy-Induced Febrile; Non-Hodgkin's Lymphoma; Multiple Myeloma; Esophageal Cancer …–
GB18
GDF15 monoclonal antibody antagonist
GDF15Phase 1Cachexia; Cancer; Cancer Cachexia (CC)Sep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07237464GB18Phase 1Cancer Cachexia (CC)OncologyJan 2026
NCT06711523PegfilgrastimPhase 3Neutropenia, Chemotherapy-Induced FebrileOncologyJun 2026
NCT06520163PegfilgrastimPhase 3Non-Hodgkin's LymphomaOncologyAug 2026
NCT06520176PegfilgrastimPhase 3Multiple MyelomaOncologyDec 2026
NCT03571633PegfilgrastimPhase 2HER2-positive Breast CancerOncologyJan 2027
NCT06363370Human interferon α1b Inhalation SolutionPhase 3Respiratory Syncytial Virus InfectionsInfectious diseaseJun 2027
NCT07519564GB18Phase 1Cachexia; CancerOncologySep 2027
NCT03731442PegfilgrastimPhase 3Esophageal CancerOncologyOct 2027
NCT00433420PegfilgrastimPhase 3Breast CancerOncologyDec 2027
NCT07553351GB06Phase 3Growth Hormone Deficiency (GHD)Metabolic and endocrineJul 2028
NCT01624805PegfilgrastimPhase 2Aplastic AnemiaHematologyJun 2029
NCT02375204PegfilgrastimPhase 3Germ Cell TumorOncologyJun 2031

Targets

GH1 (1) GDF15 (1) IFNA1 (1) CSF3R (1)

Companies with the same targets

Xiamen Amoytop Biotech Changchun GeneScience Pharmaceutical Intervene Immune CatalYm AVEO Pharmaceuticals Pfizer Nanjing King-Friend Biochemical Pharmaceutical CSL Behring Savara Spectrum Pharmaceuticals

Companies built like this

Guangzhou Gloria Biosciences Xynomic Pharmaceuticals Dizal Pharmaceuticals Evopoint Biosciences Tolmar

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.